A Multicenter, Open-Label Study to Determine the Effect of iv. [intravenous] Zoledronic [zoledronic] Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer.

Trial Profile

A Multicenter, Open-Label Study to Determine the Effect of iv. [intravenous] Zoledronic [zoledronic] Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone metastases; Breast cancer; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 23 Feb 2009 Additional location Hungary identified as reported by ClinicalTrials.gov, last updated 23-Feb-09.
    • 23 Feb 2009 Actual patient numbers (80) added as reported by ClinicalTrials.gov.
    • 20 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top